1. Clusterin ameliorates tau pathology in vivo by inhibiting fibril formation.
- Author
-
Wojtas AM, Carlomagno Y, Sens JP, Kang SS, Jensen TD, Kurti A, Baker KE, Berry TJ, Phillips VR, Castanedes MC, Awan A, DeTure M, De Castro CHF, Librero AL, Yue M, Daughrity L, Jansen-West KR, Cook CN, Dickson DW, Petrucelli L, and Fryer JD
- Subjects
- Aged, Alzheimer Disease genetics, Alzheimer Disease metabolism, Alzheimer Disease pathology, Alzheimer Disease physiopathology, Animals, Anxiety physiopathology, Humans, In Vitro Techniques, Mice, Mice, Knockout, Middle Aged, Pick Disease of the Brain genetics, Pick Disease of the Brain metabolism, Pick Disease of the Brain pathology, Pick Disease of the Brain physiopathology, Protein Aggregation, Pathological metabolism, Protein Aggregation, Pathological pathology, Protein Aggregation, Pathological physiopathology, Tauopathies metabolism, Tauopathies pathology, Tauopathies physiopathology, Clusterin genetics, Clusterin metabolism, Protein Aggregation, Pathological genetics, Tauopathies genetics, tau Proteins metabolism
- Abstract
The molecular chaperone Clusterin (CLU) impacts the amyloid pathway in Alzheimer's disease (AD) but its role in tau pathology is unknown. We observed CLU co-localization with tau aggregates in AD and primary tauopathies and CLU levels were upregulated in response to tau accumulation. To further elucidate the effect of CLU on tau pathology, we utilized a gene delivery approach in CLU knock-out (CLU KO) mice to drive expression of tau bearing the P301L mutation. We found that loss of CLU was associated with exacerbated tau pathology and anxiety-like behaviors in our mouse model of tauopathy. Additionally, we found that CLU dramatically inhibited tau fibrilization using an in vitro assay. Together, these results demonstrate that CLU plays a major role in both amyloid and tau pathologies in AD.
- Published
- 2020
- Full Text
- View/download PDF